Key words
Gymnema sylvestre
- Asclepiadaceae - gymnemagenin - rlm - Caco-2 - pharmacokinetics - LC-MS/MS
Abbreviations
AUC:
area under the curve
CLapp,int
:
apparent/intrinsic clearance
EfR:
efflux ratio
GG:
gymnemagenin
IS:
internal standard
IV:
intravenous
LC-MS/MS:
liquid chromatography-tandem mass spectrometry
LY:
lucifer yellow
NADP:
nicotinamide adenine dinucleotide phosphate
NRS:
reduced NADP regenerating system
Papp,A–B/B–A
:
apparent permeability (apical to basal/basal to apical)
P-gp:
permeability glycoprotein
QC:
quality control
RLM:
rat liver microsomes
Introduction
Gymnema sylvestre (Retz.) Schult. (Apocynaceae; syn. Periploca sylvestris Retz.) is a traditionally used medicinal plant with reported use as a remedy for
diabetes mellitus and stomachic and diuretic problems. The plant extract is also used
in folk, Ayurvedic, and homeopathic systems of medicine [1]. G. sylvestre occurs mainly in the Deccan peninsula of western India, Tropical Africa, Vietnam,
Malaysia, and Srilanka and is widely available in Japan, Germany, and the USA as a
health food [2]. In the last 10 years, several products under brand names such as Body Slatto Tea®,
Gymnema®, Gymnema Diet®, Sugar Off®, Glucoset®, Cinndrome X®, and Pilisoft® have flooded
the global markets as health foods and cosmetics [3]. Gymnemic acid and GG are believed to be the major active compounds of G. sylvestre, and GG, which enters the circulation after hydrolysis of gymnemic acids, is a common
genin for most of the gymnemic acids [4], [5], [6].
It has been a clinical concern that herbal products containing a number of natural
compounds can cause pharmacokinetic interactions with modern medicines, particularly
in combination. Therefore, detailed studies of the commonly consumed herbal products
with a particular interest to safety and related pharmacokinetics need to be done.
Among these issues the pharmacokinetic parameter for herbal products having numerous
components can probably be addressed with the help of phytomarker as a representative
molecule. So far, only a few programs have been established to study the pharmacokinetics
and pharmacodynamics of herbal medicines, as was originally proposed by the WHO Guidelines
for the assessment of herbal medicines.
Evaluation of in vitro pharmacokinetic properties has become mandatory in industrial drug discovery research
to speed up the discovery process, reduce the failure rate at the final stage, minimize
time and cost, and guide medicinal chemists to modify the compoundʼs structures to
get pharmacokinetically acceptable compounds [7]. Usually by using the “in vitro T1/2 method”, CLapp,int is determined by measuring the first order rate constant for consumption of the substrate
at a low concentration. This preclinical in vitro drug metabolism data is considered to have a good correlation with in vivo pharmacokinetics data, which is further used to predict human pharmacokinetic parameters
[8].
Evaluation of the drug transport mechanism is becoming increasingly important in drug
delivery and pharmacokinetics research. Thus, the Caco-2 cell monolayer has a lot
of importance as a reliable and high-throughput in vitro model to evaluate intestinal passive permeability as well as P-gp efflux. P-gp has
been identified in rats and human tissue such as the intestines, liver, brain, and
kidneys, suggesting that P-gp function may contribute to drug absorption, distribution,
and elimination [9]. For orally administered compounds, permeability through the Caco-2 cell monolayer
correlates well with in vivo absorption in humans [10], [11].
A comprehensive knowledge of in vitro pharmacokinetics, permeability, the role of P-gp, and their correlation with the
in vivo data of GG is important for the interpretation of the pharmacology and toxicology
of this herb, G. sylvestre, and its different formulations containing the same.
In the present work, the oral bioavailability of GG in terms of Caco-2 permeability
(Papp,A–B) and the P-gp efflux ratio (Papp,B–A/Papp,A–B) was studied after 21 days of cell culture. The in vitro intrinsic half-life (T1/2,int) and apparent intrinsic clearance (CLint,app) of GG was also measured after incubation with RLM at 37.5 °C. Finally, attempts
were made to develop a simple, sensitive, and robust LC-MS/MS method, and our method
is believed to be advantageous compared with previously published methods [12] and has been validated according to the US Food and Drug Administrationʼs Guidance
for Industry [13] for the determination and quantification of GG in rat plasma following a single
oral dose and intravenous administration of GG using dexamethasone as an internal
standard, and finding a correlation of WinNonlin calculated pharmacokinetic parameters.
Results
In positive electrospray ionization, GG and dexamethasone showed intense Q1 [M + H]+ ions at m/z 507.4 and 393.2, respectively. The daughter ions were at m/z 471.4 and 147.2 and observed after fragmentation for GG and IS, respectively, which
were monitored in MRM (multiple reaction monitoring) to quantify GG in the plasma.
The linear equation of the standard curve was obtained by regressional analysis of
the peak area ratio of analyte to internal standard versus nominal concentration with
a weighting factor of 1/x2. The calibration curve was linear in the concentration range of 0.98–1000.00 ng/mL
with an average regression coefficient, slope, and intercept of 0.9974 ± 0.0014, 0.0011 ± 0.00 004,
and 0.0004 ± 0.00 003, respectively.
The back-calculated concentration values for all QCs run in six triplicates at each
concentration level, i.e., lower limit of quantitation (LLOQ, 0.98 ng/mL), lower quality
control (LQC, 2.94 ng/mL), medium quality control (MQC, 400 ng/mL), and higher quality
control (HQC, 800 ng/mL) on three different occasions, were used to assess the accuracy
and precision of the method. The inter-run and intra-run precision and accuracy for
the various concentrations ranged from 1.76–6.75 % and 97.74–106.75 %, and 3.11–5.57 %
and 98.74–103.87 %, respectively. The mean extraction recovery and matrix effect in
the plasma at the LQC, MQC, and HQC levels were 87.41 %, 98.81 %, and 90.52 %, and
2.76 %, 3.67 %, and 3.06 %, respectively.
All the QC samples stored at − 70 °C were found to be stable for at least one month.
The back calculated concentration values for all QC samples at each concentration
level after 24 h in the autosampler at 4 °C as well as the plasma samples standing
at room temperature for 8 h and three freeze-thaw cycles of GG showed a good accuracy
(92.86–104.43 %), which indicated that the compound was stable in specified conditions
in the rat plasma.
In the RLM stability study, there was a 60 min sample without a cofactor for the test
and QC samples to determine non-metabolic degradation. The parent area detected in
T = 60 min without cofactor samples by LC-MS/MS for GG, desipramine, metoprolol, and
verapamil was comparable to the T = 0 min sample. This indicated that GG, desipramine,
metoprolol, and verapamil did not undergo chemical (non-metabolic) degradation. The
T1/2,ints of GG, desipramine, metoprolol, and verapamil were 7.31 ± 0.51, 5.87 ± 0.54, 37.57 ± 1.53,
and 4.26 ± 0.13 min, respectively, and the CLint,apps were 190.08 ± 13.01, 237.33 ± 22.48, 36.93 ± 1.50, and 325.33 ± 10.07 µL/min/mg
of protein, respectively [14] ([Table 1]).
Table 1 Summary of observed intrinsic half-life and in vitro clearance in rat liver microsomes along with scaled in vivo clearance.
|
Compound
|
Intrinsic T1/2,int (min)
|
In vitro CLint,app (µL/min/mg)
|
In vivo scaled CL'int (L/h/kg)
|
|
Gymnemagenin
|
7.31 ± 0.51
|
190.08 ± 13.01
|
24.12 ± 1.65
|
|
Desipramine
|
5.87 ± 0.54
|
237.33 ± 22.48
|
30.11 ± 2.83
|
|
Metoprolol
|
37.57 ± 1.53
|
36.93 ± 1.50
|
4.76 ± 0.16
|
|
Verapamil
|
4.26 ± 0.13
|
325.33 ± 10.07
|
41.59 ± 1.27
|
Atenolol is a low permeable compound without efflux and is transported by passive
diffusion. Furosemide is also a low permeable compound with a high efflux ratio and
a transporter(s) is involved for permeation through the Caco-2 cell monolayer. Carbamazepine
is transported by passive diffusion due to it having high permeability, whereas verapamil
also belongs to the high permeable group, but blocks P-gp with an efflux ratio > 2.
So, considering the permeability rank and efflux ratio, the above compounds were selected
for Caco-2 as quality controls.
The Papp values across the Caco-2 cell monolayer for A to B of GG, atenolol, furosemide, carbamazepine,
and verapamil were determined. In this study, the Papp for QC compounds as well as the permeability rank were comparable with the literature
values [10], [15], [16], [17]. The permeability rank of the test and QC compounds were done according to “low”,
if Papp < 2.5 × 10− 6 cm/sec, and “high”, if Papp ≥ 2.50 × 10− 6 cm/sec. The Papp,A–B and Papp,B–A were determined based on the following equation [14]:
Papp = [Va/(area × time)] × (area of acceptor well/area of donor)
where Va = volume of acceptor well (in mL) = 0.25, area = surface area of the membrane (cm2) = 0.0804, and time = time of incubation (seconds) = 9000.
The EfR, or the ratio of effective permeability for a drug, was calculated based on
the following equation:
EfR = (Papp,B–A/Papp,A–B)
It was found that GG showed poor permeability (1.31 ± 0.19 × 10− 6 cm/sec) across A to B and a high Papp,B–A (31.89 ± 0.76 × 10−6) with a high EfR 24.49 ± 3.05. The permeability values along with the efflux ratios
of GG, atenolol, carbamazepine, verapamil, domperidon, and quinidine are presented
in [Table 2].
Table 2 Caco-2 permeability (A to B and B to A) and P-gp efflux ratio of GG.
|
Compound
|
Avg Papp × 10− 6 cm/sec; n = 6
|
Permeability rank
|
|
A to B
|
B to A
|
Ratio
|
|
Gymnemagenin
|
1.31 ± 0.19
|
31.89 ± 0.76
|
24.49 ± 3.05
|
Low
|
|
Furosemide
|
0.07 ± 0.02
|
11.68 ± 0.24
|
167.71 ± 16.94
|
Low
|
|
Atenolol
|
0.31 ± 0.05
|
ND
|
ND
|
Low
|
|
Verapamil
|
9.02 ± 0.44
|
63.34 ± 8.91
|
7.03 ± 0.34
|
High
|
|
Carbamazepine
|
33.34 ± 1.49
|
40.10 ± 1.58
|
1.20 ± 0.05
|
High
|
|
Domperidone
|
2.56 ± 0.12
|
50.14 ± 3.15
|
18.90 ± 0.31
|
High
|
|
Quinidine
|
4.03 ± 0.21
|
32.28 ± 2.57
|
8.02 ± 0.11
|
High
|
A significant increase of the TEER value was observed during the cell culture, indicating
a good integrity of the Caco-2 cell monolayer. A little increase in the TEER value
(328.67 ± 11.56 Ω cm2) was found between days 15 and 20. Assessment of the integrity of the Caco-2 cell
monolayer was also determined by the LY permeability test using a fluorescence measurement.
If the Papp of LY exceeds 1 × 10− 6 cm/sec, then it is assumed that the integrity of the Caco-2 cell monolayer has been
improper and the test compound will be retested by another experiment. Wells having
more than 1 % fluorescence intensity with respect to 0.1 mg/mL of the initial donor
solution of LY were not considered for the permeability calculation because of poor
membrane integrity.
Different pharmacokinetic parameters were determined by noncompartmental analysis
using WinNonlin 6.3 from plasma concentration versus time profile for oral and IV
administration at 5 and 1 mg/kg dose, respectively ([Fig. 1]). The results of the pharmacokinetic study revealed poor oral bioavailability (14.18 ± 2.38 %)
of GG with a Cmax of 45.91 ± 5.89 ng/mL and a Tmax of 0.44 ± 0.13 h following oral administration. GG showed short terminal half-lives
(T1/2) of 0.41 ± 0.03 and 1.33 ± 0.12 h following IV and oral administration, respectively.
It was also observed that GG is rapidly metabolized and quickly eliminated from the
body with a high clearance (CL) of 53.49 ± 9.23 and 7.49 ± 0.81 L/kg/h, while the
total exposure (AUC0-α
) was found to be 95.53 ± 16.02 ng.h/mL and 134.74 ± 15.77 ng × h/mL after oral and
IV administration, respectively ([Table 3]). For IV and PO, the plasma exposure beyond 4 h and 8 h, respectively, was below
quantitation levels.
Fig. 1 Mean ± SD plasma exposure profile of GG following oral and IV administration at 5 mg/kg
and 1 mg/kg, respectively, in rats.
Table 3 Evaluation of pharmacokinetic parameters of GG following IV and oral administration.
|
Route-dose
|
IV – 1 mg/kg (n = 6)
|
PO – 5 mg/kg (n = 6)
|
|
Pharmacokinetic parameters
|
Mean ± SD
|
Mean ± SD
|
|
Kel: terminal rate of elimination; NA: not applicable; ND: not determined; Vd: volume of distribution
|
|
AUC(0-t) (ng × h/mL)
|
134.09 ± 15.78
|
89.65 ± 14.90
|
|
AUC(0-α) (ng × h/mL)
|
134.74 ± 15.77
|
95.53 ± 16.02
|
|
Cmax (ng/mL)
|
NA
|
45.91 ± 5.89
|
|
Tmax (h)
|
NA
|
0.44 ± 0.13
|
|
Kel (h−1)
|
1.71 ± 0.12
|
0.52 ± 0.04
|
|
T1/2 (h)
|
0.41 ± 0.03
|
1.33 ± 0.12
|
|
CL (L/h/kg)
|
7.49 ± 0.81
|
53.49 ± 9.23
|
|
Vd (L/kg)
|
1.53 ± 0.31
|
ND
|
|
% F
|
–
|
14.18 ± 2.38
|
Discussion
G. sylvestre is a potent antidiabetic herb that is used for many polyherbal formulations. Gymnemic
acid as well as GG are the two major phytoconstituents having antidiabetic activity
[4] and are the most accepted phytomarkers used for characterization as well as validation
of G. sylvestre. Although G. sylvestre is a clinically well-accepted herb, correlation of its RLM stability, Caco-2 permeability,
and efflux with its bioavailability following oral and IV administration of GG in
rats is yet to be investigated.
The aim of the in vitro kinetic study was to determine the in vitro CLint by the substrate depletion approach, since formal kinetic characterization and quantification
of the specific metabolites are not required [18]. Accordingly, the in vitro intrinsic half-life and clearance were found to be 7.31 ± 0.51 min and 190.08 ± 13.01 µL/min/mg
of protein, respectively. The CLint was calculated based on the dose/AUC0–inf instead of the more rigorous approach using enzyme kinetics data that consider maximum
enzyme velocity, Vmax, and Km. This simplified approach is probably more appropriate and sophisticated, since the
substrate concentration (1 µM) is much below the apparent Km for substrate turnover and thus no significant product inhibition- or mechanism-based
inactivation of the enzyme can be expected [19]. To determine assay specificity and enzyme activity, verapamil, desipramine, and
metoprolol were used as quality control samples that have a range of CLint,app from 30 to 350 µL/min/mg of protein [14]. From our in vitro enzyme kinetic studies, it was found that GG is rapidly metabolized by the hepatic
oxidative enzyme(s), which indicates that the liver is the major organ of clearance
for GG. This rate of metabolism and enzyme activities on GG are truly reflected in
rat in vivo pharmacokinetic studies, where we have observed GG to be a poorly bioavailable (%
F ~ 14) compound with short terminal half-lives 0.41 h and 1.33 h following IV and
oral administration, respectively.
The purpose of our transport study in the Caco-2 monolayer is to rank the test item
GG based on Papp,A–B and ascertain whether the test compound is a substrate of the efflux transporter.
These data can well be considered to influence oral bioavailability of GG in rats.
Generally, an EfR value of < 1.20 or 1.50 indicates a mere involvement of passive
diffusion for drug transportation, whereas an EfR value exceeding unity suggests that
the compound may be a substrate of efflux transporters at the apical membrane [20], [21]. In our study, it was observed that GG has poor A to B permeability, 1.31 × 10− 6 cm/sec, and high B to A permeability, 31.89 × 10− 6 cm/sec, with a high EfR of 24.49. Low Caco-2 permeability with a high EfR is expected
to render a poor systemic exposure of GG. Accordingly, to confirm the abovementioned
in vitro enzyme kinetic findings and Caco-2 results, we have performed an oral and IV pharmacokinetic
study of GG in rats.
The results of the pharmacokinetic study revealed poor systemic exposure with less
than 15 % oral bioavailability and a mean Cmax, of 45.91 ng/mL achieved within half an hour following oral administration. GG showed
short terminal half-lives of less than 0.5 h and 1.33 h following IV and oral administration,
respectively. This indicated a rapid metabolism of GG followed by quick elimination
from the body. An observed higher in vivo clearance indicated that GG was a poor bioavailable compound and the reduced AUC
for the plasma profile was probably due to the rapid elimination of GG from the central
compartment. The in vivo pharmacokinetic study was performed taking a single dose through PO and IV administration,
which is a better representation for the pilot study.
A good metabolic stability in liver microsomes, optimum Caco-2 permeability, and pharmacokinetic
profile in preclinical species are the major characteristics for a potential and safe
drug molecule that could be further extrapolated in humans before clinical trials.
Here, we have tried to establish the in vitro and in vivo pharmacokinetics, permeability, and efflux concerns for GG, and correlate its in vitro findings with that of the in vivo data. To conclude, it will be interesting to mention that although we have observed
a good in vitro – in vivo correlation of GG, one of the major phytomarkers of G. sylvestre, it probably possesses poor drug-like properties in terms of metabolic stability
and permeability, at least with the limits of our experimental conditions. Further
studies are required to investigate the contribution of different transporters in
absorption and efflux as well as extrahepatic factors/metabolism that may have reduced
the overall bioavailability of GG in our study.
Materials and Methods
Chemicals and reagents
HPLC grade water (resistivity of 18 MΩ × cm) generated from a Milli Q water purification
system, methanol, and acetonitrile (HPLC grade) were purchased from JT Baker. DMSO
(≥ 99.9 %), KH2PO4 (≥ 99 %), K2HPO4 (≥ 99 %), MgCl2 hexahydrate (≥ 99 %), atenolol (≥ 98 %), furosemide (≥ 98 %), carbamazepine (≥ 98 %),
domperidon (≥ 98 %), desipramine (≥ 98 %), verapamil (≥ 99 %), metoprolol (≥ 98 %),
dexamethasone (≥ 97 %), quinidine (≥ 80 %), and LY were purchased from Sigma, and
RLMs were from Invitrogen. NADP (≥ 98 %), Glucose-6-phosphate (99 %) and glucose-6-phosphate
dehydrogenase were from SRL, and GG (> 95 %) was from Natural Remedies. The Caco-2
cell layer from ATCC, apical and basal plates from BD, and all cell culture reagents
and media were obtained from Gibco BRL Life Technology. All flasks were obtained from
Coring Science Product Division, and other chemicals were of analytical grade.
Instrumentation and chromatographic conditions
The liquid chromatography part consisted of an LC-20ADvp pump, system controller,
CTC PAL (HTS) autosampler, and tandem mass spectrometer with an ESI source in API-4000.
Detection and quantification were performed using Analyst 1.4.2 software.
Analyte separation was achieved on a Luna C18 column (2 × 30 mm, 5 µm) with a Security Guard C18 guard column (4 × 3.0 mm i. d.) from Phenomenex with a flow rate of 0.8 mL/min. The
mobile phases were 0.1 % formic acid in water (A) and a mixture of acetonitrile, methanol,
and water at 50 : 30 : 20 with 0.1 % acetic acid (B). The gradient elution program
was as follows: first 72 s of only A for washing and then 84 s for the gradient up
to 100 % B; this was continued for the next 60 s and the total run time was 4.0 min.
Samples after the Caco-2 and RLM study were analyzed in LC-MS/MS using a Luna phenyl
hexyl cartridge (2 × 10 mm, 5 µm) with a flow rate of 0.80 mL/min. The mobile phases
were water containing 0.1 % v/v formic acid (A) and a mixture of acetonitrile and
water (80 : 20) containing 0.1 % formic acid and 2 mM ammonium acetate (B).
In vitro kinetic study using rat liver microsomes
GG along with the quality control compounds desipramine, metoprolol, and verapamil
were incubated for 0, 5, 10, 20, 30, and 60 min in a temperature controlled water
bath of 37 °C at a 1 µM concentration in the absence of the blank and with another
60 min sample without the cofactor (WC) for chemical degradation control. We followed
the experimental procedure/protocol that has already been reported, with minute modifications
[22]. Briefly, 100 µL of incubation mixture contained RLM (0.5 mg/mL), NADP (1.3 mM),
glucose-6-phosphate (3.3 mM), and glucose-6-phosphate dehydrogenase (0.4 U/mL) containing
MgCl2 (3.3 mM) solution in phosphate buffer pH 7.4. All reactions were started by the addition
of NRS in a 96 deep-well plate and were carried out for the abovementioned time points.
The reaction was terminated by the addition of 300 µL of ice-cold acetonitrile and
mixed, followed by centrifugation at 4000 rpm for 15 min at 15 °C. One hundred and
twenty µL of supernatant were diluted with 120 µL of water, and 25 µL were injected
into the LC-MS/MS.
Time on the X axis and ln (area of analyte) on the Y axis were plotted in a semi-log
plot to calculate the slope. Intrinsic T1/2 was calculated by dividing − 0.693 with the slope. In vitro CLint was scaled to an in vivo CL′int (in units of mL/min/kg) using microsomal protein (mg/g of liver) and average liver
weight (g of liver/kg of body weight) according to the following formula:
CL′int = (0.693/in vitro T1/2) × (mL of incubation volume/mg of microsomal protein) × (45 mg microsomal protein/g
of liver) × (20
a
g of liver/kg of body weight)
a: 20 and 45 g of liver/kg of body weight were used for human and rat respectively
[19].
Caco-2 permeability study (A–B and B-A)
A to B cell plating and culture: The Caco-2 cell line was obtained from ATCC and cells were seeded at 6.3 × 104 cells/cm2 and grown in a medium containing Dulbeccoʼs modified Eagleʼs medium (DMEM) comprised
of 4.5 g/L glucose and supplemented with 10 % (v/v) fetal bovine serum (FBS), 1 %
(v/v) glutamine, penicillin (100 U/mL), streptomycin (100 µg/mL), and 1 % (v/v) Minimum
Essential Medium (MEM) nonessential amino acids. Cultures were maintained at 37 °C
in an atmosphere of 95 % air and 5 % CO2 with controlled humidity. The medium was changed in every 2–3 days. Routine passing
of all cell stocks was carried out in 75 cm2 flasks, and experiments were done on passages #25–30.
Sevnty-five µL of 2.5 × 105 cells/mL and 40 mL of media were transferred to the apical wells and to the feeder
tray, respectively. The plates were placed in an incubator (37 °C, 5 % CO2, and controlled humidity). The first media change was given between 40–72 h and cells
were grown for 21 days with a media change every alternate day.
B to A cell plating and culture: 25 µL of 7.5 × 105 cells/mL were transferred to the bottom side (keeping the plate upside down) of apical
wells. The plate (upside down position) was kept in an incubator (37 °C, 5 % CO2, and controlled humidity) for 2 h. The plate was turned right side up. Seventy-five
µL of media/well to the apical plate and 40 mL of media to the feeder tray were added.
Transport study
Permeability assay A to B: The apical wells were washed with buffer pH 6.5 and basal wells washed with buffer
pH 7.4. Two hundred and fifty µL of buffer pH 7.4/well were added to the basal plate.
Seventy-five µL of GG, atenolol, furosemide, carbamazepine, and verapamil solutions
(2 µM) in buffer pH 6.5 were added to the apical wells (n = 6).
Permeability assay B to A: The apical wells were washed with buffer pH 7.4 and basal wells with buffer pH 6.5.
Two hundred and fifty µL of buffer pH 6.5/well were added to the basal plate. Seventy-five
µL of GG, domperidon, furosemide, carbamazepine, quinidine, and verapamil solutions
(2 µM) in buffer pH 7.4 were added to the apical wells (n = 6). The apical plate was
placed on to the basal plate with a lid to prevent evaporation. The assembly was incubated
at 37 °C for 2.5 h under 95 % air and 5 % CO2 with controlled RH. The apical plate was separated after incubation and aliquots
from the acceptor wells were taken, diluted, and quantified by LC-MS/MS along with
the initial donor samples.
Membrane integrity
To optimize the membrane integrity of the Caco-2 monolayer, the TEER was determined
during the cell culture. A little increase in the TEER value was found between days
15 and 20. Another membrane integrity test post the Caco-2 experiment was performed
using lucifer yellow by fluorimetry. Solutions in the apical wells were discarded
by inverting the plate and soaking them on tissue paper very carefully. Phosphate
buffer pH 7.4 250 µL/well was added to the basal plate. Seventy-five µL of LY (0.1 mg/mL)
in buffer pH 7.4 per well were added to the apical plate. The apical plate was placed
on to the basal plate with a lid. The assembly was incubated at 37 °C for 1 h under
5 % CO2 and 95 % air. The apical plate was separated after incubation, and 100 µL of solution
from the basal wells were transferred for the fluorescence (Ex: 432 nm, Em: 530 nm)
measurement. A fluorescence of 100 µL buffer pH 7.4 only and 100 µL LY (0.1 mg/mL)
were also measured.
Animal study
Pharmacokinetic study: The experiments were conducted using male Wistar rats under the care and use of
laboratory animals in accordance with the guidelines prescribed by the Institutional
Ethical Committee (constituted under the guidelines of Committee for the Purpose of
Control and Supervision of Experiments on Animals, CPCSEA, Reg. No. 367). The study
was approved by the ethical committee on 11/12/2014 and the approval number is AEC/PHARM/1407/2014.
Animals were acclimatized individually in a cage under a 12/12-h light dark cycle,
22 ± 2 °C temp, 50 ± 20 % RH 5 days prior to the studies and maintained on an 18 %
casein-containing semisynthetic diet with free access to food and water. Pharmacokinetic
studies with GG were carried out in male (180–200 g) Wistar rats after oral and intravenous
administration of GG at a dose of 5 mg/kg and 1 mg/kg, respectively. A solution formulation
of GG was made in 10 % DMSO, 30 % propylene glycol, and the rest was 5 % glucose solution
with a dose volume of 5 mL/kg for oral and 2 mL/kg for IV. Animals were divided into
two groups – Gr-I (n = 6) for oral and Gr-II (n = 6) for IV. About 130 µL of whole
blood were collected at predetermined time points (Pre-dose, 0.08, 0.25, 0.5, 1, 2,
4, 8, and 24 h) via jugular vein cannulation, and normal saline solution was supplemented
in each time point after sample collection. The collected samples were centrifuged
at 2500 rpm for 10 min at 4 °C and the collected plasma was stored at − 70 °C until
bioanalysis.
Method validation: The validation of the bioanalytical method in plasma was carried out for selectivity,
linearity, precision, accuracy, recovery, matrix effect, and stability according to
the principles of the Food and Drug Administration [13] industry guide. An 11-point calibration curve covering a range of 0.98–1000 ng/mL
of GG was prepared in duplicate and analyzed in three different runs on three separate
days with six replicates of the LLOQ (0.98 ng/mL), LQC (2.94 ng/mL), MQC (400 ng/mL),
and HQC (800 ng/mL) samples. The curves were fitted using a linear regression method
with weighting 1/x2.
The selectivity, specificity, and intraday and interday precision and accuracy of
the method were assessed. The extraction recovery (ER) and matrix effect of GG after
protein precipitation was determined at three concentration levels, and the extraction
recovery of IS was also carried out at a single (70 ng/mL) concentration. The ME was
evaluated in the present study as proposed by Matuszewski et al. [23].
Recovery (%) = (peak area of the extracted analyte × 100 / peak area of the non-extracted
analyte mixed with blank matrix extract)
ME (%) = {1 - (response for post-extraction spiked drug) / (response in solvent)} × 100
The stability of GG was evaluated as part of the method validation. The processed
sample stability in the autosampler at 4 °C for 12 h, stability of GG in the biomatrix
after 8 h exposure on the bench-top, long-term stability (30 days) of the spiked QC
samples stored at − 70.00 °C, and freeze-thaw stability (3 cycles) were evaluated.
The standard stock solution of GG (analyte) and dexamethasone (IS) were prepared in
DMSO (2.00 mg/mL) for each. Then an intermediate stock (100.00 µg/mL) for GG and IS
were prepared in DMSO. The working stock solutions 50 000.00, 25 000.00, 12 500.00,
6250.00, 3125.00, 1562.50, 781.25, 390.63, 195.31, 97.66, and 48.83 ng/mL for the
calibration curve (CC), and 146.48, 20 000.00, and 40 000.00 ng/mL for QCs were prepared
from intermediate stock in DMSO. CC and QC samples were prepared by spiking 2 µL from
the working stock to 98 µL blank matrix to get final concentrations of 1000.00, 500.00,
250.00, 125.00, 62.50, 31.25, 15.63, 7.81, 3.91, 1.95, and 0.98 ng/mL and 2.94 (LQC),
400.00 (MQC), and 800.00 (HQC) ng/mL for the CC and QC samples. Five µL of 350.00 ng/mL
(IS) were spiked in each sample. All standard and IS stock solutions were stored in
polypropylene vials at 2–8 °C for further use.
Sample preparation for plasma: All plasma samples along with linearity and QC samples were analyzed using the validated
LC-MS/MS method. The plasma sample aliquot (30 µL) was taken into a V-bottom shallow
96-well plate and direct precipitation of the matrix was done by adding an ice-cold
mixture (70/30, v/v) of acetonitrile and methanol (3 × sample volume). The mixture
was mixed in a thermomixer for 8 min and centrifuged at 4000 rpm for 15 min at 15 °C.
Sixty µL of clear supernatant was mixed with 50 µL of water, and 20 µL of aliquot
was injected into the LCMS/MS.
Pharmacokinetic analysis: Pharmacokinetic parameters were calculated from the plasma concentration data following
oral and IV administration ([Fig. 1]) by a noncompartmental method using WinNonlin 6.3. The area under the plasma concentration-time
curve, AUC0–tlast, was calculated from time 0 h to the last quantifiable time point by the linear trapezoidal
method. The time at which Cmax was achieved (Tmax), the apparent maximum plasma concentration (Cmax) and the terminal elimination rate constant (Kel), terminal half-life (T1/2), clearance (CL), volume of distribution (Vd), total exposure AUC0–last, and AUC0–α
were determined ([Table 3]).
Supporting information
Mass spectrometry and chromatography data of GG and dexamethasone, as well as intraday
and interday precision and accuracy data of GG, and stability data are available as
Supporting Information.
Acknowledgements
We express our sincere thanks to AICTE-RPS, New Delhi, India, and UGC UPE-II for providing
financial support for this study.
